JP2014507443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507443A5 JP2014507443A5 JP2013555547A JP2013555547A JP2014507443A5 JP 2014507443 A5 JP2014507443 A5 JP 2014507443A5 JP 2013555547 A JP2013555547 A JP 2013555547A JP 2013555547 A JP2013555547 A JP 2013555547A JP 2014507443 A5 JP2014507443 A5 JP 2014507443A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- indol
- triazole
- phenyl
- mercapto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446099P | 2011-02-24 | 2011-02-24 | |
| US61/446,099 | 2011-02-24 | ||
| US201161491531P | 2011-05-31 | 2011-05-31 | |
| US61/491,531 | 2011-05-31 | ||
| PCT/US2012/026268 WO2012141796A2 (en) | 2011-02-24 | 2012-02-23 | Prostate cancer therapy with hsp90 inhibitory compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014507443A JP2014507443A (ja) | 2014-03-27 |
| JP2014507443A5 true JP2014507443A5 (enExample) | 2015-04-09 |
Family
ID=46614578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013555547A Pending JP2014507443A (ja) | 2011-02-24 | 2012-02-23 | Ｈｓｐ９０阻害化合物での前立腺癌治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140051665A1 (enExample) |
| EP (1) | EP2678014A2 (enExample) |
| JP (1) | JP2014507443A (enExample) |
| CN (1) | CN103391779A (enExample) |
| AU (1) | AU2012243289A1 (enExample) |
| CA (1) | CA2827739A1 (enExample) |
| WO (1) | WO2012141796A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2035396T1 (sl) | 2006-05-25 | 2014-08-29 | Synta Pharmaceuticals Corp. | Triazolne spojine, ki modulirajo aktivnost HSP90 |
| US8450500B2 (en) | 2008-06-04 | 2013-05-28 | Synta Pharmaceuticals Corp. | Pyrrole compounds that modulate HSP90 activity |
| WO2010017545A2 (en) | 2008-08-08 | 2010-02-11 | Synta Pharamceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US9126953B2 (en) * | 2008-08-08 | 2015-09-08 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| HUE044867T2 (hu) | 2011-05-12 | 2019-11-28 | Proteostasis Therapeutics Inc | Proteosztázis szabályzók |
| CA2840986A1 (en) | 2011-07-07 | 2013-01-10 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| TW201618775A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物 |
| PL3179991T3 (pl) | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
| IL273195B2 (en) * | 2017-09-27 | 2024-04-01 | Targimmune Therapeutics Ag | Castration-resistant prostate cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP1817295B1 (en) * | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| AU2008287367B2 (en) * | 2007-08-13 | 2012-02-23 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| EP2575810A1 (en) * | 2010-05-24 | 2013-04-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| WO2012116061A1 (en) * | 2011-02-23 | 2012-08-30 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with radiotherapy |
-
2012
- 2012-02-23 AU AU2012243289A patent/AU2012243289A1/en not_active Abandoned
- 2012-02-23 EP EP12743551.9A patent/EP2678014A2/en not_active Withdrawn
- 2012-02-23 CN CN2012800101340A patent/CN103391779A/zh active Pending
- 2012-02-23 JP JP2013555547A patent/JP2014507443A/ja active Pending
- 2012-02-23 US US14/001,465 patent/US20140051665A1/en not_active Abandoned
- 2012-02-23 WO PCT/US2012/026268 patent/WO2012141796A2/en not_active Ceased
- 2012-02-23 CA CA2827739A patent/CA2827739A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507443A5 (enExample) | ||
| JP2013537229A5 (enExample) | ||
| JP2013508378A5 (enExample) | ||
| US10500193B2 (en) | Combination therapy of HSP90 inhibitors with platinum-containing agents | |
| JP2014533299A5 (enExample) | ||
| AU2011302344B2 (en) | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients | |
| US9439899B2 (en) | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors | |
| US20130171105A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor | |
| US20160120849A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor | |
| US20130331357A1 (en) | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors | |
| US20130156755A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor | |
| JP2017523997A5 (enExample) | ||
| JP2015516439A (ja) | Ｈｓｐ９０阻害化合物で癌を治療すること | |
| JP2014533299A (ja) | Ｂｒａｆ阻害剤とｈｓｐ９０阻害剤の組合せ療法 | |
| JP2009534386A5 (enExample) | ||
| JP2010523669A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2017523167A5 (enExample) | ||
| US20140051665A1 (en) | Prostate cancer therapy with hsp90 inhibitory compounds | |
| JP2017537882A5 (enExample) | ||
| JP2012532100A5 (enExample) | ||
| RU2018114518A (ru) | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) | |
| JP2011057693A5 (enExample) | ||
| JP2012505871A5 (enExample) | ||
| JP2019529518A5 (enExample) |